SCHEMBL1904403

SCHEMBL1904403

Cc1ccc2c(C(=O)Nc3nnc(-c4ccco4)o3)cc(-c3ccccc3)nc2c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 9/20 0.82
RAB9A P51151 3/20 0.58
NPC1 O15118 2/20 0.58
LMNA P02545 7/20 0.57
KDM4E B2RXH2 4/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
HTT P42858 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
ALOX12 P18054 2/20 0.57
CHEK1 O14757 1/20 0.56
AURKA O14965 1/20 0.56
DAPK3 O43293 1/20 0.56
PRKD3 O94806 1/20 0.56
PAK4 O96013 1/20 0.56
NTRK1 P04629 1/20 0.56
RET P07949 1/20 0.56
MET P08581 1/20 0.56
PIM1 P11309 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1897448 0.94 STAT3 (0.81) STAT3RAB9ANPC1LMNAKDM4E
SCHEMBL1898648 0.92 STAT3 (0.87) STAT3RAB9ANPC1LMNAKDM4E
SCHEMBL1899809 0.91 STAT3 (1.00) STAT3RAB9ANPC1LMNAKDM4E
SCHEMBL29382140 0.91 STAT3 (1.00) STAT3RAB9ANPC1LMNAKDM4E
SCHEMBL1899382 0.89 STAT3 (0.82) STAT3RAB9ANPC1LMNAKDM4E
SCHEMBL1906135 0.89 STAT3 (0.82) STAT3RAB9ANPC1LMNAKDM4E
SCHEMBL1905449 0.86 STAT3 (0.84) STAT3RAB9ANPC1LMNAKDM4E
SCHEMBL1904287 0.86 STAT3 (0.76) STAT3RAB9ANPC1LMNAKDM4E
SCHEMBL1899540 0.85 STAT3 (0.89) STAT3RAB9ANPC1LMNAKDM4E
SCHEMBL1899563 0.85 STAT3 (0.89) STAT3RAB9ANPC1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 EP disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 US disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B STAT3 1/4885RAB9A 2148/4885NPC1 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.